FATE News and Press, Fate Therapeutics Inc. From 11/09/21

Ahead of its data presentations in two major medical meetings in 2021, Citi has upgraded Fate Therapeutics (NASDAQ:FATE) to Buy from Neutral, citing over a 30% decline in its share price during the year. Today, the biotech announced that the Society for Immunotherapy of Cancer (SITC) Com...

Company to Host Virtual Investor Event on Monday, November 15 SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer,...

Image source: The Motley Fool. Fate Therapeutics, inc (NASDAQ: FATE) Q3 2021 Earnings Call Nov 4, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Fate Therapeutics, inc (FATE) Q3 2021 Earnings Call Transcript

Fate Therapeutics, Inc. (FATE) Q3 2021 Earnings Conference Call November 4, 2021, 05:00 PM ET Company Participants Scott Wolchko - President and CEO Ed Dulac - CFO Wayne Chu - SVP, Clinical development Conference Call Participants Michael Yee - Jefferies Mike Ulz - Morgan Stanley Alethia Youn...

Fate Therapeutics (NASDAQ:FATE): Q3 GAAP EPS of -$0.45 beats by $0.13. Revenue of $14.23M (+88.2% Y/Y) beats by $5.56M. Press Release Cash, cash equivalents and investments as of September 30, 2021 were $803.6 million. For further details see: Fate Therapeutics EPS beats by $0.13, beats...

Initiated Enrollment in Phase 1 Clinical Studies of FT538 and FT576 for R/R Multiple Myeloma FT596 Interim Phase 1 Data of 14 Patients in Single-Dose Escalation Cohorts 2 and 3 for R/R Lymphoma Showed 71% ORR and 50% CR; Differentiated Safety Profile with Two Low-Grade Events of...

FT596 Oral and FT516 Poster Presentations to Highlight Updated Clinical Data for Relapsed / Refractory Lymphoma on Monday, December 13 Company to Host Virtual Investor Event on Tuesday, December 14 SAN DIEGO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDA...

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion in Assets Under Management. After the Q2-2021 13F filings, the consensus holdings were updated, 6 stocks were removed and 6 added from the u...

SAN DIEGO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today annou...

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion in Assets Under Management. After the Q2-2021 13F filings, the consensus holdings were updated, 6 stocks were removed and 6 added from the u...